Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every six weeks in patients with recurrent malignant glioma: Results of the phase I NABTT 9806 clinical trial

Abstract only

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 22; no. 14_suppl; p. 1533
Main Authors:	New, P. Z., Grossman, S., Mikkelsen, T., Batchelor, T., Phuphanich, S., Carson, K., Fisher, J., Craig, M., Cagnoni, P.
Format:	Journal Article
Language:	English
Published:	15-07-2004
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!